Aprea Therapeutics APRE Stock
1.7 USD
{{ price }}
-5.555551%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
United States
Exchange
NasdaqCM
Market Cap
9.24M USD
LOW - HIGH [24H]
1.67
-
1.85 USD
VOLUME [24H]
89.88K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.35 USD
Aprea Therapeutics Price Chart
Aprea Therapeutics APRE Financial and Trading Overview
| Aprea Therapeutics stock price | 1.7 USD |
| Previous Close | 3.4 USD |
| Open | 3.42 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 1000 |
| Day's Range | 3.3 - 3.44 USD |
| 52 Week Range | 0.47 - 25.8 USD |
| Volume | 26.19K USD |
| Avg. Volume | 13.38K USD |
| Market Cap | 12.72M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.35 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15 USD |
APRE Valuation Measures
| Enterprise Value | -16997310 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8736264 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.48048472 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.501 |
Trading Information
Aprea Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -78.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 25.8 USD |
| 52 Week Low | 0.47 USD |
| 50-Day Moving Average | 3.81 USD |
| 200-Day Moving Average | 8.33 USD |
APRE Share Statistics
| Avg. Volume (3 month) | 13.38K USD |
| Avg. Daily Volume (10-Days) | 21.03K USD |
| Shares Outstanding | 3.73M |
| Float | 2.45M |
| Short Ratio | 2.35 |
| % Held by Insiders | 16.05% |
| % Held by Institutions | 14.58% |
| Shares Short | 23.62K |
| Short % of Float | 0.75% |
| Short % of Shares Outstanding | 0.63% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | -282.29% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -33917800 USD |
| Net Income Avi to Common (ttm) | -109105224 USD |
| Diluted EPS (ttm) | -64.75 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 31M USD |
| Total Cash Per Share (mrq) | 8.31 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 7.574 |
| Book Value Per Share (mrq) | 7.097 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -22494888 USD |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Aprea Therapeutics
| Country | United States |
| State | PA |
| City | Doylestown |
| Address | 3805 Old Easton Road |
| ZIP | 18902 |
| Phone | 617 463 9385 |
| Website | https://www.aprea.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 9 |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Q&A For Aprea Therapeutics Stock
What is a current APRE stock price?
Aprea Therapeutics APRE stock price today per share is 1.7 USD.
How to purchase Aprea Therapeutics stock?
You can buy APRE shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aprea Therapeutics?
The stock symbol or ticker of Aprea Therapeutics is APRE.
Which industry does the Aprea Therapeutics company belong to?
The Aprea Therapeutics industry is Biotechnology.
How many shares does Aprea Therapeutics have in circulation?
The max supply of Aprea Therapeutics shares is 5.43M.
What is Aprea Therapeutics Price to Earnings Ratio (PE Ratio)?
Aprea Therapeutics PE Ratio is now.
What was Aprea Therapeutics earnings per share over the trailing 12 months (TTM)?
Aprea Therapeutics EPS is -2.35 USD over the trailing 12 months.
Which sector does the Aprea Therapeutics company belong to?
The Aprea Therapeutics sector is Healthcare.
Aprea Therapeutics APRE included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
| NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}